PGAM
SABS icon

Princeton Global Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Princeton Global Asset Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$1.35K – 680
2024
Q3 		$1.35K Hold
500
– – ﹤0.01% 618
2024
Q2 		$1.55K Hold
500
– – ﹤0.01% 603
2024
Q1 		$2.27K Buy
+500
New +$2.75K ﹤0.01% 531

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Princeton Global Asset Management's SABS Position: Q4 2024 in Review

Princeton Global Asset Management sold out of SAB Biotherapeutics (SABS) in Q4 2024, closing a stake of 500 shares — an estimated $1.35K sold.

Princeton Global Asset Management first reported a position in SABS in Q1 2024 and held it in 3 quarters. The position peaked at $2.27K in Q1 2024. 25 funds tracked by Wall St. Rank hold SABS as of Q4 2024.

  • Princeton Global Asset Management reported no remaining SAB Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 500 SAB Biotherapeutics shares in Q4 2024, an estimated $1.35K.
  • Princeton Global Asset Management first reported a position in SAB Biotherapeutics in Q1 2024 and held it in 3 quarters.
  • Princeton Global Asset Management's SAB Biotherapeutics position peaked at $2.27K in Q1 2024.
  • 25 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2024.

Based on Princeton Global Asset Management's 13F filing for Q4 2024, filed 24 Jan 2025.